Yara Abdou, MD, UNC School of Medicine, Chapel Hill, NC, provides an overview of the clinical utility of the 21-gene recurrent score (RS) in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer and 1-3 positive lymph-nodes established from the Phase III RxPONDER (NCT01272037) trial. The primary objective of the trial was to determine the effect of chemotherapy on invasive disease–free survival (iDFS) and whether the effect was influenced by the RS. Secondary end points included distant relapse–free survival. The trial demonstrated there was no benefit to chemotherapy in postmenopausal woman with an RS of 25 or less, whereas in premenopausal woman there was a benefit of chemotherapy regardless of RS. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть